蛋鸡首免乙型脑炎病毒后卵黄抗体变化规律的研究

本试验旨在研究疫苗、免疫剂量和注射方式对卵黄抗体效价规律的影响,探讨制备抗猪乙型脑炎病毒卵黄抗体蛋鸡的最佳免疫程序。选用无免疫褐羽蛋鸡180只,随机分成18组,每组10只。1、2组均为对照组,注射无菌生理盐水;3~10组采用皮下和肌肉两种注射方式,并依次注射灭活苗0.2、0.5、1.0和1.5 mL;11~18组同样采取两种注射方式,依次免疫相同剂量弱毒苗。各试验组分别于免疫前1 d、免疫后第3、7、10、14、18、21和28天采集当日鸡蛋6枚,提取卵黄抗体,测定效价。试验结果显示,1~6、11、12组卵黄抗体效价均为0,未产生明显免疫应答;7~10组注射灭活苗后7 d,平均卵黄抗体效价达到峰值,抗体持续时间为14 d;13~18组注射弱毒苗后14 d达到最高值,抗体持续时间为21 d;注射剂量相同但注射方式不同的两组之间比较,卵黄抗体效价差异不显著（P>0.05）;相同注射方式,相同疫苗的各试验组间,随着免疫剂量的增加卵黄抗体效价逐渐加强,且差异显著（P<0.05）。以上结果表明,肌肉或皮下两种注射方式,蛋鸡产生明显免疫应答至少需要免疫灭活苗1.0 mL或弱毒苗0.5 mL。比较弱毒苗与灭活苗,灭活苗刺激机体产生的抗体速度较快,但维持时间较短;较少剂量弱毒苗就可刺激机体产生抗体,但速度慢、维持时间长。     

Duration of immunity in foxes vaccinated orally with ERA vaccine in a bait.

Red foxes (Vulpes vulpes) vaccinated orally with the ERA strain of rabies vaccine in a bait were challenged after 83 mo. Ten of 11 foxes that had seroconverted following vaccination resisted challenge with a virulent rabies virus which produced clinical signs of rabies in 6 of 6 unvaccinated foxes. Five of 11 vaccinated animals retained titers of rabies virus neutralizing antibody throughout the period. Although 6 of 11 had no detectable antibody at the time of challenge, 5 of these 6 resisted challenge and had an anamnestic response, as indicated by elevated titers of antibody when measured at day 77 postchallenge. These results show that foxes can be immunized successfully with a single oral dose of ERA vaccine, probably with protection against a lethal rabies challenge, for at least 7 y.     

Study on the Change Rule of Egg Yolk Antibody in Laying Hens after First Immunization by Japanese Encephalitis Virus

The purpose of this experiment was to study the immunization rule of the egg yolk antibody affected by different vaccines,immunization dose and injection ways and further to discuss the optimal immunization procedures of the laying hens for the preparation of egg yolk antibody against swine Japanese encephalitis virus.180 brown laying hens without any vaccines were selected and divided into 18 groups randomly,each group of 10 hens.Groups 1,2 were the control groups,injected with the sterile saline;Groups 3 to 10 were injected with subcutaneous or intramuscular injection,and the vaccine was injected with 0.2,0.5,1.0 and 1.5 mL successively.Groups 11 to 18 were also adopted two kinds of injection,followed by the same dose of vaccine immunization.Six eggs of each experimental group were gathered before immune day and after 3,7,10,14,18,21 and 28 days,the egg yolk antibody was extracted and the titer was determined.As a result,the egg yolk antibody titers of groups 1 to 6,11 and 12 were all 0,and no significant immune response produced;The hens from 7 to 10 groups were injected with the inactivated vaccine.After 7 days,the average antibody titer reached the peak,and the duration of the antibody was 14 days.The hens from 13 to 18 groups were injected with the attenuated virus vaccine.After 14 days,the average antibody titer reached the highest value,and the duration of the antibody was 21 days.The egg yolk antibody titers were not significantly different in the two compared experiment groups with the same injection dose but with different injection ways (P>0.05).With the same injection way of each experiment group,and the difference was significant (P>0.05).Compared with some groups with the same injection and vaccine,the titer of yolk antibody was gradually increased with the increase of the immune dose,and the difference was significant (P<0.05).The results showed that,no matter intramuscular or subcutaneous injection,in order to produce a significant immune response to hens,the immune antigen dose was 1.0 mL inactivated vaccine or 0.5 mL attenuated vaccine at least.Compared with the attenuated and inactivated vaccine,inactivated vaccine stimulated the body to produce the antibody faster,but the maintenance time was shorter;The lower dose of attenuated vaccine could stimulate the body to produce antibodies,but the speed was slower,the maintenance time was longer.     

Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice

OBJECTIVE: To evaluate the effect of various routes of administration and number of doses of 3 commercially produced rabies vaccines on serum antibody responses and protection in mice challenged by intracerebral injection with fixed-strain rabies virus. ANIMALS: 2,213 mice. PROCEDURE: Inactivated, adjuvanted rabies vaccines were administered to mice in either 2, 1, or 0 (control) doses via IP, IM, and SC routes, and mice were challenged intracerebrally with fixed-strain rabies virus. RESULTS: Vaccination route and dose number significantly influenced serum antibody responses and protection from rabies virus challenge, independent of vaccine strain origin and mouse strain, although mouse age significantly affected results. Extended challenge studies revealed that IM vaccination of mice resulted in the highest serum neutralizing antibody responses and protection levels equivalent to IP vaccination. Even multiple doses administered SC (a vaccination route used in dogs) resulted in poor serum anti-rabies neutralizing antibody responses in mice and were far less protective than other routes. CONCLUSIONS AND CLINICAL RELEVANCE: Findings suggest possible improvements for the current rabies vaccine potency test in mice by using 1 dose, the IM route, and a delayed time of challenge. These modifications would more closely model vaccination practices in target species and yield more accurate information regarding primary immunogenicity of a vaccine.     

African Horse-Sickness Killed-Virus Tissue Culture Vaccine

Formalized African horse-sickness (AHS) type 9 virus cultivated in monkey kidney stable (MS) cell cultures was experimentally used for immunizing horses. Inactivated vaccines prepared either from viscerotropic or neurotropic type 9 AHS virus produced antibodies in vaccinated horses. Immunity developed in all horses vaccinated with various amounts of the vaccine, and protected them from infection, when challenged 5 weeks after vaccination.     

H9亚型禽流感病毒流行毒株交叉免疫攻毒保护试验

采用1998-2009年在河北、河南及山东分离的3株禽流感H9亚型流行毒株,分别制备灭活疫苗,免疫SPF鸡,免疫后21 d,采血测定HI抗体,然后用从上述3个地区及北京分离的共5株禽流感H9亚型流行毒株进行攻击,观察不同时期及地点分离的H9亚型流行毒株的交叉免疫攻毒保护效果。结果显示,用不同时期及地点的3个分离毒株所制备出的灭活疫苗免疫鸡后,各免疫组试验鸡H9亚型禽流感的HI抗体效价均明显上升,不同毒株灭活疫苗所诱导产生的HI抗体效价存在着不同程度的差异,用同源毒株作为抗原测定免疫组鸡的血清样品,可获得较高的HI抗体效价。攻毒试验结果证明,对不同时期及地点分离的禽流感H9亚型流行毒株间产生了较好的交叉保护力。用1998年分离的WD98株制备出的灭活疫苗对目前的流行毒株仍具有较好的保护效力。     

Vaccination of pigs against Aujeszky's disease by the intradermal route using live attenuated and inactivated virus vaccines.

Inactivated and live Aujeszky's disease virus vaccines were administered intradermally using a special device without a needle. The 88 pigs were vaccinated at the beginning of the fattening period, both under experimental conditions and in commercial herds. All the pigs were challenged at the end of the fattening period in isolation units. The same vaccines were also injected intramuscularly. Vaccination by the intradermal route induced good protection, similar to that conferred with live virus vaccine injected intramuscularly. The inactivated virus vaccine was not as effective when it was injected by the intradermal route. In animals vaccinated intradermally, there were no local lesions in the meat, but very small nodules were found in the dermis; these do not affect carcass quality. The effects of challenge exposure depended on the initial health of the animals, and a synthetic value (delta G) was used to interpret the data. In fattening pigs, intradermal vaccination required less animal constraint than intramuscular injection; administration could be verified by the presence of a papule at the site of inoculation, and pigs could be vaccinated while they were feeding. Injection without a needle also helps avoid bacterial contamination under farm conditions.     

三个厂家猪瘟活疫苗免疫效果比较试验

在同一条件下对3个厂家生产的猪瘟细胞源活疫苗进行了免疫效果评价试验,并与猪瘟传代细胞苗免疫效果进行比较。结果发现3个厂家生产的猪瘟细胞源活疫苗存在一定差异,2个厂家的免疫效果较好,1个厂家的免疫效果较差。猪瘟传代细胞苗免疫效果优于猪瘟细胞源活疫苗,猪瘟传代细胞苗免疫1次,抗体合格率高,持续时间长,猪瘟细胞源活疫苗要免疫两次才能获得比较好的效果。同时,我们发现高致病性猪蓝耳病活疫苗（JXA1-R株）对猪瘟抗体产生有一定影响。     

猪繁殖与呼吸综合征疫苗研究现状

猪繁殖与呼吸综合征(PRRS)是一种对养猪业危害严重的传染病,猪繁殖与呼吸综合征病毒(PRRSV)为有囊膜的单股正链RNA病毒,且具有高度的变异性,有美洲型和欧洲型两个血清型。猪肺泡巨噬细胞(PAM)、恒河猴胎肾细胞系MA-104及源于MA-104的传代细胞系(如Marc-145、CL-2621、HS.2H和CRL-1171)对PRRSV敏感。预防该病的常规疫苗有灭活疫苗和弱毒疫苗两种。通常以特定种毒在适当细胞系中培养增殖,经灭活或致弱,加入佐剂制得相应疫苗。灭活疫苗交叉保护性差,但使用安全;弱毒疫苗抗体产生快、持续时间长、保护力强,但源毒能在猪群中持续存在而有安全隐患。     

Studies of ERA/BHK-21 rabies vaccine in skunks and mice.

ERA rabies vaccine virus grown in BHK-21 13S cells (ERA/BHK-21) and street rabies virus were titrated in mice by intracerebral, intranasal and intramuscular inoculation. Mice were also given undiluted ERA/BHK-21 in baits. Skunks were given undiluted ERA/BHK-21 in baits and by intramuscular, intranasal and intestinal inoculation. Virus neutralizing antibody titers against rabies virus were measured over a three month observation period. The surviving skunks were challenged by intramuscular inoculation with rabies street virus from a skunk salivary gland suspension. When titrated in mice, ERA/BHK-21 had titers of 10(7.0), 10(5.2) and 10(3.9) median lethal doses per mL by the intracerebral, intranasal and intramuscular routes, respectively. All skunks (8/8) inoculated intranasally developed paralytic rabies by 12 days after exposure to ERA/BHK-21 virus. None of the skunks that developed vaccine-induced rabies had infectious virus in the submandibular salivary glands. Vaccine-induced rabies also occurred in 1/8 skunks in the intramuscularly inoculated group and in 1/8 in the intestinally inoculated group. The survival rates of challenged skunks in the various groups were as follows: intramuscular, 7/7; intestinal, 2/7; bait, 0/8; and control, 0/8. These results indicate that ERA/BHK-21 virus has a significant residual pathogenicity in mice and in skunks by some routes of inoculation. Skunks given vaccine intramuscularly were protected against challenge, while those skunks given the vaccine in baits were not.     

Vaccination of day-old broiler chicks against Newcastle disease and infectious bursal disease using commercial live and/or inactivated vaccines

Day-old broilers were administered live and/or inactivated vaccines to assess vaccine efficacy against challenge with Newcastle disease (ND) and infectious bursal disease (IBD). Chicks were from commercial breeder pullets vaccinated against ND and IBD using several live vaccine primers followed by an inactivated ND-IBD vaccine at 18 weeks. The most efficacious initial ND-IBD vaccination program was live ND virus by eye drop and live IBD vaccine injected subcutaneously (SQ) followed 2 hours later with inactivated ND-IBD vaccine SQ. The next two most efficacious programs were live vaccine alone and the inactivated vaccine only. Inactivated vaccine given SQ had no adverse effect on live IBD vaccine given 2 hours earlier in a similar site. Administration of inactivated vaccine by vent was not as efficacious as administration SQ. A booster of a second live ND-IBD vaccine drinking water at 18 days significantly increased levels of circulating antibody, regardless of the initial vaccination program.     

Priming of multiple T cell subsets by modified-live and inactivated bovine respiratory syncytial virus vaccines

T cell activity is a critical component of immunity to bovine respiratory syncytial virus (BRSV). We tested the effects of immunization by modified-live and inactivated BRSV vaccines on cell-mediated and humoral immunity in young calves. The two forms of vaccine stimulated similar serum neutralizing antibody production, although the early kinetics of those responses differed. CD4+, CD8+, and gammadelta T cells were analyzed before and after immunization for BRSV-specific in vitro recall responses, as evaluated by CD25 upregulation measured by flow cytometry. Modified-live virus (MLV) primed each of the three subsets for statistically significant in vitro responses to antigen. Inactivated vaccine also primed each T cell population for significant antigen-driven CD25 upregulation, including responses by CD4+ and gammadelta T cells that were stronger and longer-lasting than those primed by MLV. Monoclonal antibody was used in additional assays to block MHC class I during incubation of BRSV antigen with peripheral blood mononuclear cells from an animal in the inactivated vaccine group. The recall response by CD8+ T cells was more inhibited by this treatment than the other subsets, further suggesting that the inactivated vaccine had primed antigen-specific CD8+ T cells. In summary, the data indicate that balanced BRSV-specific T cell responses can be induced by inactivated, as well as modified-live, conventional vaccines, which may implicate an alternative pathway of MHC class I antigen presentation.     

THE SEROLOGICAL RESPONSE OF CHICKENS TO OIL EMULSION VACCINES CONTAINING THE V4 STRAIN OF NEWCASTLE DISEASE VIRUS

SUMMARY Experiments were conducted with vaccines containing the V₄ strain of Newcastle disease virus (NDV). Both living aqueous vaccines and vaccines consisting of virus incorporated in an oil emulsion were used. The calculated dose of virus contained in the oil emulsion vaccine was 10^8,7 50% embryo infectious doses (EID₅₀) per bird dose. Haemagglutinin inhibition (HI) antibody levels of 8 are presumed protective. One-day-old chicks with low levels of maternal antibody were vaccinated intraocularly with 10^6,3EID₅₀ of live vaccine, and concurrently with oil emulsion vaccine. Presumed protective levels of antibody were present at two weeks post vaccination and were maintained for at least seven weeks longer. When adult birds 15 weeks old with no previous exposure to NDV were vaccinated intraocularly with 10^6,7EID₅₀ per bird, protective levels of antibody were produced within a week. Unvaccinated birds put in contact with the vaccinated birds produced similar antibody levels within 14 days. Revaccination with oil emulsion vaccine after antibody levels had fallen resulted in a rapid response with high levels of antibody. When antibody-free adult commercial birds with an unknown history of exposure to NDV were vaccinated intramuscularly with oil emulsion vaccine, high antibody levels were produced for at least 21 weeks. Concurrent intraocular inoculation with 10^7,0EID₅₀ live virus did not enhance the response. Natural infection of unvaccinated birds occurred during the experiment. This was detected by the presence of HI antibody levels of short duration. When antibody-free commercial birds were inoculated intramuscularly with oil emulsion vaccine containing 10^6,0, 10^7,0, or 10^8,0EID₅₀ per bird dose, 100% of birds inoculated with the highest dose produced presumed protective levels of antibody within two weeks, as compared with a 5-week delay when using the 10^7,0EID₅₀ per bird dose.     

表达H5亚型禽流感病毒HA基因的重组鸡痘病毒在水禽的免疫效力

利用表达 H5亚型禽流感病毒血凝素基因的重组鸡痘病毒 ( r FPV- HA)和油乳剂全病毒灭活疫苗分别接种商品鹅 ,评价疫苗在水禽的免疫保护作用。结果发现 ,免疫后 2 1 d,r FPV- HA免疫组 HI抗体检测为阴性 ,灭活疫苗免疫组HI抗体阳性率为 70 % ;用 H5亚型禽流感病毒攻击后 ,与阴性对照组相比 ,r FPV - HA免疫组鹅的口腔和泄殖腔排毒率降低 ,病理变化减轻 ,感染鹅易康复 ,保护率为 80 % ,总体保护效力达到灭活疫苗水平。结果表明 r FPV - HA免疫家鹅可诱导良好保护 ,显示出了良好的应用前景     

Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals

The envelope glycoprotein D of equine herpesvirus 1 (EHV-1 gD) has been shown in laboratory animal models to elicit protective immune responses against EHV-1 challenge, and hence is a potential vaccine antigen. Here we report that intramuscular inoculation of EHV-1 gD produced by a recombinant baculovirus and formulated with the adjuvant Iscomatrix elicited virus-neutralizing antibody and gD-specific ELISA antibody in the serum of over 90% of adult mixed breed horses. The virus-neutralizing antibody responses to EHV-1 gD were similar to those observed after inoculation with a commercially available killed EHV-1/4 whole virus vaccine. Intramuscular inoculation of EHV-1 gD DNA encoded in a mammalian expression vector was less effective in inducing antibody responses when administered as the sole immunogen, but inoculation with EHV-1 gD DNA followed by recombinant EHV-1 gD induced increased gD ELISA and virus-neutralizing antibody titres in six out of seven horses. However, these titres were not higher than those induced by either EHV-1 gD or the whole virus vaccine. Isotype analysis revealed elevated gD-specific equine IgGa and IgGb relative to IgGc, IgG(T) and IgA in horses inoculated with EHV-1 gD or with the whole virus vaccine. Following inoculation of pregnant mares with EHV-1 gD, their foals had significantly higher levels of colostrally derived anti-gD antibody than foals out of uninoculated mares. The EHV-1 gD preparation did not induce a significant mean antibody response in neonatal foals following inoculation at 12 h post-partum and at 30 days of age, irrespective of the antibody status of the mare. The ability of EHV-1 gD to evoke comparable neutralizing antibody responses in horses to those of a whole virus vaccine confirms EHV-1 gD as a promising candidate for inclusion in subunit vaccines against EHV-1.     

Evaluation of killed and modified live porcine rotavirus vaccines in cesarean derived colostrum deprived pigs

Twenty-eight cesarean derived, colostrum deprived (CDCD) piglets were used to evaluate the efficacy of killed and modified live rotavirus (MLV) vaccines against challenge with virulent A-1 and A-2 rotaviruses. Two killed rotavirus vaccines were evaluated: an experimental vaccine and a commercially available vaccine. Efficacy parameters included: average daily weight gains, rotavirus shedding in feces, morbidity incidence and duration, and rotavirus serum antibody conversion post-vaccination and post-challenge. Piglets vaccinated orally/intramuscularly with the modified live vaccine were completely protected from A-1 and A-2 virulent rotavirus challenge. Nonvaccinated control piglets and piglets receiving killed rotavirus vaccines developed diarrhea, shed virus and exhibited reduced weight gains post-challenge. Only the MLV rotavirus vaccine was able to prevent virus shedding in feces after virulent challenge. Both controls and pigs which received killed vaccines intraperitoneally, orally or intramuscularly shed virus in the feces for 7 days post-challenge and virus peak titers approached 10(7) fluorescent antibody infectious dose (FAID)50/g feces. These studies clearly reflected the inability of killed rotavirus vaccines to induce active local immunity to rotaviral diarrhea in piglets.     

猪2型圆环病毒核酸疫苗免疫效应研究

PCR扩增PCV2 ORF2和BVP22基因。将ORF2基因克隆入真核表达载体pCDNA3．1（＋），构建了pCORF2作为核酸疫苗免疫小白鼠。同时将具有蛋白转导功能的BVP22基因分别克隆到ORF2基因的上游和下游，使二者融合表达，命名为pCORF2BVP22和pCBVP220RF2。分4组肌肉免疫BALB/c小白鼠，分别注射pCDNA3．1（＋）、pCORF2、pCORF2BVP22和pCBVP220RF2，共免疫2次，间隔2周，分别于首免后2周和二免后4周采血，ELISA法检测体液抗体。同时为在体外验证ORF2和BVP22基因的真核表达，将ORF2和BVP22基因分别克隆入pEGFP-N1载体，构建了pNORF2和pNBVP22，转染Hela细胞后在荧光显微镜下观察到了ORF2和BVP22在体外的瞬时高效表达。结果显示，通过两次免疫后，各疫苗组均产生了针对ORF2的体液抗体，同时证明BVP22可增强核酸疫苗的免疫效果，其中以BVP22在ORF2上游效果更好。本研究为防制猪2型圆环病毒感染提供了较为理想的侯选疫苗。     

A comparative study on the immune response of sheep to foot and mouth disease virus vaccine type Asia-1 prepared with different inactivants and adjuvants.

Foot and mouth disease virus type Asia-1 was inactivated either with formaldehyde or binaryethylenimine (BEI). Inactivated vaccines were prepared incorporating aluminium hydroxide gel or mineral oil as an adjuvant. The antibody response to the adult sheep was studied by ELISA and SN test for a period of 6 months. There was no difference in the antibody response between vaccines inactivated with formaldehyde or BEI. Whereas significant difference in the antibody response was observed between gel and oil vaccines. The high titres of antibody stimulated by oil vaccines persisted longer than those of gel vaccines within the period of study.     

A canine parainfluenza viral vaccine: immunogenicity and safety.

A canine parainfluenza viral vaccine was developed and shown to be safe by absence of clinical disease in vaccinated dogs and by inability to isolate vaccine virus from blood or nasopharyngeal swabs. Backpassage in susceptible dogs, using blood of vaccinated dogs, could not be demonstrated. The vaccine produced neutralizing antibody when administered either intramuscularly or subcutaneously; however, a significantly higher immune response was obtained by intramuscular inoculation. Differences in the antibody response were not produced by tenfold dilutions of vaccine virus ranging from 10(2.9) to 10(5.9) median tissue culture infective doses. The presence of neutralizing antibody was associated significantly with decreased respiratory shedding period of challenge virus by vaccinated dogs compared to seronegative control dogs. Six days after aerosol exposure to virulent challenge virus, 100% of the controls (n = 5) but only 15% of the vaccinated dogs (n = 3) shed virus. Seven days after challenge exposure, virus could not be recovered from the vaccinated dogs, but 80% of the control dogs shed virus. An anamnestic response occurred in vaccinated dogs but not in the seronegative control dogs following challenge exposure. A mild clinical disease was produced in 3 of the 5 seronegative control dogs but not in the 20 vaccinated dogs.     

Current perspectives on control of equine influenza

Influenza A viruses of the H3N8 subtype are a major cause of respiratory disease in horses. Subclinical infection with virus shedding can occur in vaccinated horses, particularly where there is a mismatch between the vaccine strains and the virus strains circulating in the field. Such infections contribute to the spread of the disease. Rapid diagnostic techniques are available for detection of virus antigen and can be used as an aid in control programmes. Improvements have been made to methods of standardising inactivated virus vaccines, and a direct relationship between vaccine potency measured by single radial diffusion and vaccine-induced antibody measured by single radial haemolysis has been demonstrated. Improved adjuvants and antigenic presentation systems extend the duration of immunity induced by inactivated virus vaccines, but high levels of antibody are required for protection against field infection. In addition to circulating antibody, infection with influenza virus stimulates mucosal and cellular immunity; unlike immunity to inactivated virus vaccines, infection-induced immunity is not dependent on the presence of circulating antibody to HA. Live attenuated or vectored equine influenza vaccines, which may better mimic the immunity generated by influenza infection than inactivated virus vaccines, are now available. Mathematical modelling based upon experimental and field data has been applied to examine issues relating to vaccine efficacy at the population level. A vaccine strain selection system has been implemented and a more global approach to the surveillance of equine influenza is being developed.